Company Filing History:
Years Active: 2023-2024
Title: Christopher Harbison: Innovator in Cancer Treatment
Introduction
Christopher Harbison is a notable inventor based in Hamilton, NJ (US). He has made significant contributions to the field of cancer treatment, particularly in the development of methods for treating LAG-3 positive tumors. With a total of 2 patents, his work is paving the way for advancements in immunotherapy.
Latest Patents
Harbison's latest patents focus on innovative methods for treating tumors in human patients. The first patent outlines a method that involves identifying a patient with a LAG-3 positive tumor and administering a PD-1 pathway inhibitor. This may include a combination of a PD-1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. The invention aims to improve response rates to treatment, particularly for patients identified as having LAG-3 positive PD-L1 positive tumors.
Career Highlights
Christopher Harbison is currently associated with Bristol-Myers Squibb Company, where he continues to work on groundbreaking cancer therapies. His expertise in the field has led to significant advancements in treatment methodologies.
Collaborations
Harbison collaborates with esteemed colleagues such as James Novotny, Jr. and Nils Lonberg. Their combined efforts contribute to the innovative research and development of cancer treatments.
Conclusion
Christopher Harbison's work in the field of cancer treatment exemplifies the impact of innovation in medicine. His patents and collaborations are crucial in advancing therapeutic options for patients with LAG-3 positive tumors.